Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
about
Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man.Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systemsThe effects of beta-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine.The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.Substantial rise in sparteine metabolic ratio during haloperidol treatment.Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man.Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?Sparteine oxidation polymorphism: a family study.Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo.Sparteine oxidation is practically abolished in quinidine-treated patients.Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.Influence of hydroxychloroquine on the bioavailability of oral metoprololDevelopment and validation of an HPLC-UV method for the simultaneous determination of the antipsychotics clozapine, olanzapine and quetiapine, several beta-blockers and their metabolites.Drug metabolism and interactions in abuse liability assessment.Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.Inhibitors of imipramine metabolism by human liver microsomes.Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps.Phenacetin O-deethylation by human liver microsomes: kinetics and propranolol inhibition.Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man.Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.
P2860
Q24541294-9488A7D9-56A6-46DA-A2B8-D777F95C4C4AQ30370390-DBFCBAD6-52DE-427D-8202-1BFE14BA63CFQ34037250-78B51BF0-E874-47E5-95C7-56B247A6F8B3Q34345780-6D0C16E0-706B-449C-8BDD-DF970710E2DEQ34347566-B21466EA-427F-4759-A136-7CD01C86AA61Q34357697-B4D2146A-71E4-45F3-B0A0-3D0393127892Q34358984-B8213276-9CDF-4617-96B8-ECED8F7D48CFQ34397040-44431439-88E0-42FB-8E30-B4F4307ACD65Q34397294-7E71D0A7-24A6-4A63-ACCE-B4D1C292E54AQ34398035-31B7887B-C00C-472E-9D12-85B5334E9F94Q34398234-5F63FEC0-39FC-46A8-B7B2-FB38EB3453B3Q34398346-F6888217-551C-4F89-97C6-1C5281C61942Q34403471-1E91018C-08D6-44D8-BFC1-8A799F6E3BAFQ34446534-0DEF5A0A-65D1-4FEA-9F7D-EC1A91A7EDEFQ34447491-57EEF47D-46D3-40A2-AE83-820B50367347Q34447859-268E0E66-8163-4C4E-9B9A-943E8B5E16C1Q34447888-AEE5EFEC-2935-4B9B-B3A0-B472489B745FQ34448258-0F0C0F23-C6A2-4746-B7C1-5E308D347CFEQ36055442-BD766EEA-F606-4AB9-AD8E-D5E7AD1E68D6Q36299177-4FCBC372-E488-4E74-BBB9-B541CDFF9EE8Q36941534-80A314C9-A272-48D1-8F64-22F386B4FB75Q38365410-9D73A70C-5E68-4606-ADEE-B73677D51C25Q40815580-C50B4CE2-E3C8-4468-AA11-405EC58FABCFQ40976937-6B307C28-80F5-417E-8D5C-587F0BBAE8C8Q41769510-AE0ECB51-4243-47FD-8B15-33396BB37B03Q42174751-13AB6DFF-AE65-45E7-8FE5-0C58AEB373F0Q42229235-B0D41B94-1678-40CB-B676-C252FBCB8C3EQ43222504-E8246519-9928-443A-84C9-B7A045AC7092Q44047581-BAAF5835-20F8-455C-946B-17CD0E2387AAQ44232254-15364D79-8E2D-49FA-942A-972DA5673AC5Q44438917-BE72D256-92FA-4098-B86F-E01BA24463E0Q44871609-AB06A3D1-DA36-40B5-850A-AD88D890093EQ46522222-A339A3C7-FF56-4C75-9375-442C2DAEE4EFQ53409559-F4F1D8D0-2E46-494E-B4F4-E3E674114EC0
P2860
Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs
description
im Januar 1984 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 January 1984
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 1984
@uk
name
Competitive inhibition of spar ...... and other cardiovascular drugs
@en
Competitive inhibition of spar ...... and other cardiovascular drugs
@nl
type
label
Competitive inhibition of spar ...... and other cardiovascular drugs
@en
Competitive inhibition of spar ...... and other cardiovascular drugs
@nl
prefLabel
Competitive inhibition of spar ...... and other cardiovascular drugs
@en
Competitive inhibition of spar ...... and other cardiovascular drugs
@nl
P2093
P1433
P1476
Competitive inhibition of spar ...... and other cardiovascular drugs
@en
P2093
P356
10.1016/0024-3205(84)90332-1
P407
P577
1984-01-01T00:00:00Z